Study finds Tegoprazan 50 mg effective for functional dyspepsia

A recent prospective multicenter clinical trial evaluated the efficacy and safety of tegoprazan, a potassium-competitive acid blocker (P-CAB), in treating functional dyspepsia.

Patients diagnosed with functional dyspepsia were given tegoprazan 50 mg per day for 8 weeks. Symptom relief was reckoned using a dyspepsia symptom questionnaire, the Nepean dyspepsia index-Korean version (NDI -K) score, and the GERD Health-Related Quality of Life. The primary endpoint was the rate of acceptable symptom relief at the follow-up.

Out of 209 screened patients, 173 (mean age = 41.3 years) were included in the per-protocol analysis. The study found satisfactory symptom relief rates of 86.7% and 74.6% at 8 weeks and 4 weeks, respectively. Noteworthy improvements in NDI-K and GERD-HRQL scores were observed at both time points compared to the start of the treatment. The efficacy of tegoprazan was steady across different functional dyspepsia subtypes and was not affected by Helicobacter pylori status. Compared to people with just functional dyspepsia, patients with overlapping FD and GERD showed more significant improvements in symptoms. No serious drug-related adverse events were reported.

Oral Tegoprazan dosed at 50 mg provides satisfactory relief from the symptoms of functional dyspepsia, concluded Cheal Wung Huh.